Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec;50(12):9793-9803.
doi: 10.1007/s11033-023-08846-y. Epub 2023 Oct 13.

Circulating hsa-miR-221 as a possible diagnostic and prognostic biomarker of diabetic nephropathy

Marwa Sayed Abdel-Tawab  1 , Mohamed Gamal Mohamed  2 , Noha A Doudar  3 , Enas Ezzat Rateb  4 , Hoda Ramadan Reyad  5 , Naglaa Adli Abd Elazeem  5
Affiliations

Circulating hsa-miR-221 as a possible diagnostic and prognostic biomarker of diabetic nephropathy

Marwa Sayed Abdel-Tawab et al. Mol Biol Rep. 2023 Dec.

Erratum in

Abstract

Background: Diabetic nephropathy (DN), which is a chronic outcome of diabetes mellitus (DM), usually progresses to end-stage renal disease (ESRD). The DN pathophysiology, nevertheless, is not well-defined. Several miRNAs were reported to be either risk or protective factors in DN.

Methods, and results: The present study sought to inspect the potential diagnostic and prognostic value of hsa-miR-221 in DN. The study included 200 participants divided into four groups: Group 1 (50 patients with DN), Group 2 (50 diabetic patients without nephropathy), Group 3 (50 nondiabetic patients with CKD), and Group 4 (50 healthy subjects as a control group). Patients in groups 1 and 3 were further classified based on the presence of macroalbuminuria and microalbuminuria. Hsa-miR-221 expression was measured by RT- qRT-PCR. DN patients had significantly elevated serum hsa-miR-221 levels than the other groups, while diabetic patients without nephropathy exhibited elevated levels compared to both nondiabetic patients with CKD, and the control group. The DN patients with macroalbuminuria revealed significantly higher mean values of hsa-miR-221 relative to the patients with microalbuminuria. Significant positive associations were observed in the DN group between serum hsa-miR-221 and fasting insulin, fasting glucose, HOMA IR, ACR, and BMI. The ROC curve analysis of serum hsa-miR-221 in the initial diagnosis of DN in DM revealed high specificity and sensitivity.

Conclusions: It is concluded that hsa-miR-221 has the potential to be a useful biomarker for prognostic and diagnostic purposes in DN.

Keywords: Diabetes mellitus; Diabetic nephropathy; hsa-miR-221.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
The mean levels of serum hsa-mir-221 in studied subjects. a mean levels of serum hsa-mir-221 in studied groups. b mean levels of serum hsa-mir-221 in subjects with different degrees of albuminuria in diabetic nephropathy group. c mean levels of serum hsa-mir-221 in subjects with different degrees of albuminuria in nondiabetic CKD group
Fig. 2
Fig. 2
Significant correlations of serum hsa-mir-221 in the studied groups. Red dots diabetic nephropathy group, green dots diabetic without nephropathy group
Fig. 3
Fig. 3
ROC Curve Analysis of serum hsa-mir-221 in early detection of diabetic nephropathy in diabetic patients
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, Stein C, Basit A, Chan JC, Mbanya JC, Pavkov ME. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183:109119. doi: 10.1016/j.diabres.2021.109119. - DOI - PMC - PubMed
    1. Zhou B, Lu Y, Hajifathalian K, Bentham J, Di Cesare M, Danaei G, Bixby H, Cowan MJ, Ali MK, Taddei C, Lo WC. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387:1513–1530. doi: 10.1016/S0140-6736(16)00618-8. - DOI - PMC - PubMed
    1. Harding JL, Pavkov ME, Magliano DJ, Shaw JE, Gregg EW. Global trends in diabetes complications: a review of current evidence. Diabetologia. 2019;62:3–16. doi: 10.1007/s00125-018-4711-2. - DOI - PubMed
    1. Zhang XX, Kong J, Yun K (2020) Prevalence of diabetic nephropathy among patients with type 2 diabetes mellitus in China: a meta-analysis of observational studies. J Diabetes Res 2020 - PMC - PubMed
    1. Samsu N (2021) Diabetic nephropathy: challenges in pathogenesis, diagnosis, and treatment. BioMed Res Int 2021 - PMC - PubMed

MeSH terms